[go: up one dir, main page]

AR129309A1 - DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL - Google Patents

DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL

Info

Publication number
AR129309A1
AR129309A1 ARP230101179A ARP230101179A AR129309A1 AR 129309 A1 AR129309 A1 AR 129309A1 AR P230101179 A ARP230101179 A AR P230101179A AR P230101179 A ARP230101179 A AR P230101179A AR 129309 A1 AR129309 A1 AR 129309A1
Authority
AR
Argentina
Prior art keywords
formula
disorders
independently represents
alkyl
pharmaceutically acceptable
Prior art date
Application number
ARP230101179A
Other languages
Spanish (es)
Inventor
Melanie Kessler
Azely Mirre
Jens Peters
- Sager Christoph Uwe
Jean Surivet
- Williams Jodi T Philippe
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AR129309A1 publication Critical patent/AR129309A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de la fórmula (1) en donde Ar¹, R¹, R², R³, X¹, X², Y, y Z son como se describen en la descripción, a su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como productos farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de fórmula (1), y especialmente a su uso como antagonistas del receptor de orexina. Reivindicación 1: Un compuesto de fórmula (1) en donde R¹ representa alquilo (C₁₋₃), halógeno, ciclopropilo, o trifluorometilo; X¹ representa S u O; X² representa CH o N; Z representa -CH₂-, -CH(CH₃)-, o -CH₂-CH₂-; y en el fragmento de fórmula (2) R² representa de manera independiente hidrógeno, alquilo (C₁₋₃), halógeno, o alcoxi (C₁₋₃); R³ representa de manera independiente hidrógeno, o alquilo (C₁₋₃); y Y representa de manera independiente CH o N; y Ar¹ representa de manera independiente: un compuesto del grupo de fórmulas (3); o una sal farmacéuticamente aceptable del mismo. Reivindicación 14: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 11, o una sal farmacéuticamente aceptable del mismo, para utilizar en la prevención o en el tratamiento de trastornos del sueño, trastornos de ansiedad, trastornos de adicción, disfunciones cognitivas, trastornos del estado de ánimo, trastornos del apetito, o síntomas neuropsiquiátricos en la demencia.The present invention relates to compounds of the formula (1) wherein Ar¹, R¹, R², R³, X¹, X², Y, and Z are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (1), and especially to their use as orexin receptor antagonists. Claim 1: A compound of formula (1) wherein R¹ represents (C₁₋₃)alkyl, halogen, cyclopropyl, or trifluoromethyl; X¹ represents S or O; X² represents CH or N; Z represents -CH₂-, -CH(CH₃)-, or -CH₂-CH₂-; and in the fragment of formula (2) R² independently represents hydrogen, (C₁₋₃)alkyl, halogen, or (C₁₋₃)alkoxy; R³ independently represents hydrogen, or (C₁₋₃)alkyl; and Y independently represents CH or N; and Ar¹ independently represents: a compound of the group of formula (3); or a pharmaceutically acceptable salt thereof. Claim 14: A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, appetite disorders, or neuropsychiatric symptoms in dementia.

ARP230101179A 2022-05-13 2023-05-12 DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL AR129309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2022063015 2022-05-13

Publications (1)

Publication Number Publication Date
AR129309A1 true AR129309A1 (en) 2024-08-07

Family

ID=86604875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230101179A AR129309A1 (en) 2022-05-13 2023-05-12 DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL

Country Status (3)

Country Link
AR (1) AR129309A1 (en)
TW (1) TW202400149A (en)
WO (1) WO2023218023A1 (en)

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472964A (en) 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
ATE286897T1 (en) 2000-11-28 2005-01-15 Smithkline Beecham Plc MORPHOLINE DERIVATIVES AS ANTAGONISTS AT OREXIN RECEPTORS
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
US7432270B2 (en) 2001-05-05 2008-10-07 Smithkline Beecham P.L.C. N-aroyl cyclic amines
MXPA03011706A (en) 2001-06-28 2004-03-19 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists.
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
ATE344261T1 (en) 2002-09-18 2006-11-15 Glaxo Group Ltd CYCLIC N-AROYLAMINS AS OREXIN RECEPTOR ANTAGONISTS
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
DK1751111T3 (en) 2004-03-01 2015-02-09 Actelion Pharmaceuticals Ltd SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives
UA93903C2 (en) 2006-03-15 2011-03-25 Актелион Фармасьютикалз Лтд Tetrahydroisoquinoline derivatives to enhance memory function
PL2069332T3 (en) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
EP2079690B1 (en) 2006-09-29 2010-09-15 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
ATE496043T1 (en) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS
CL2007003827A1 (en) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM N- (2-AZA-BICYCLE (3.1.0) HEX-3-ILMETIL) AMIDA; AND ITS USE TO PREVENT OR TREAT DEPRESSION, NEUROSIS, SCHIZOPHRENIA, ANXIETY, ADDICTIONS, EPILEPSY, PAIN, HEART DISEASES, AMONG OTHERS.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (en) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others.
JP2010526869A (en) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド 2-cyclopropyl-thiazole derivatives
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
KR20100041805A (en) 2007-07-03 2010-04-22 액테리온 파마슈티칼 리미티드 3-aza-bicyclo[3.3.0]octane compounds
TW200911242A (en) 2007-07-03 2009-03-16 Glaxo Group Ltd Novel compounds
RU2478099C2 (en) 2007-07-27 2013-03-27 Актелион Фармасьютиклз Лтд 2-aza-bicyclo[3,3,0]octane derivatives
JP2010534646A (en) 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド Trans-3-Aza-bicyclo [3.1.0] hexane derivative
JP2010540429A (en) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (en) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd TETRAHYDROQUINOLINE DERIVATIVES
AU2009215243A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509911A (en) 2008-11-26 2012-04-26 グラクソ グループ リミテッド New compounds
EP2358711A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
UY32277A (en) 2008-12-02 2010-05-31 Glaxo Group Ltd DERIVATIVES OF N - {[1R, 4S, 6R) -3- (2-PIRIDINILCARBONIL) -3-AZABICICLO [4.1.0-IL} METHYL} -2HETEROARYLAMINE AND USE OF THE SAME
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EA201171293A1 (en) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-AZABICYCLO [4.1.0] HEPTANS APPLIED AS ANTAGONISTS OF OREXIN
US9150566B2 (en) * 2011-11-08 2015-10-06 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
TW201613891A (en) * 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
WO2016086357A1 (en) * 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
JP7182562B2 (en) 2017-05-03 2022-12-02 イドーシア ファーマシューティカルズ リミテッド Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
JP7391012B2 (en) 2017-09-01 2023-12-04 クロノス セラピューティクス リミテッド Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists

Also Published As

Publication number Publication date
TW202400149A (en) 2024-01-01
WO2023218023A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
AR119731A1 (en) NLRP3 INFLAMASOME INHIBITORS
AR108101A1 (en) GPR119 AGONIST COMPOUNDS AND METHOD TO TREAT DISEASES AND AFFECTIONS THROUGH GPR119
AR097325A1 (en) RINGED PIRROLS
ECSP066520A (en) DERIVATIVES OF DIHYDROBENZOFURANYL ALCANAMINE AND METHODS FOR USE
AR054035A1 (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USE OF THE SAME
AR112099A1 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES AND THEIR USE
NO20054206L (en) biphenyl
AR037682A1 (en) ACETYLENE DERIVATIVES THAT HAVE ANTAGONIST ACTIVITY FOR RECEPTORS HUMAN METABOTROPIC GLUTAMATE, PHARMACEUTICAL COMPOSITION, A COMBINATION AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
AR036598A1 (en) DERIVATIVES OF 4,5-DIHIDRO-1H-PIRAZOL THAT HAVE POWERFUL CB1 ANTAGONIST ACTIVITY
ES2193875B2 (en) DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
AR056204A1 (en) DERIVATIVES OF INDANO AS ANTAGONISTS OF MCH RECEPTORS, METHODS FOR THEIR PREPARATION, SYNTHESIS INTERMEDIARIES OF THE SAME, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF RELATED DISEASES
AR087668A1 (en) DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
AR088535A1 (en) DERIVATIVES OF AMIDAS OF REPLACED AMINO ACIDS WITH N-UREA AS FORMUL RECEPTOR MODULATORS PEPTIDE RECEIVER OF TYPE 1 RECEPTOR (FPRL-1)
UY29393A1 (en) NEW DERIVATIVES OF AMIDAS, ACCEPTABLE PHARMACEUTICAL SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
AR081426A1 (en) PIRAZOL DERIVATIVES INHIBITORS OF THE SIGMA RECEIVER
AR108102A1 (en) GPR119 AGONIST COMPOUNDS AND METHOD TO TREAT DISEASES AND AFFECTIONS THROUGH GPR119
JP2015520770A5 (en)
AR105522A1 (en) DERIVATIVES OF REPLACED AMIDA THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN
AR111494A1 (en) ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT
AR101196A1 (en) SUBSTITUTED PYRIMIDINE COMPOUNDS
AR054508A1 (en) BENCILPIPERAZINE COMPOSITE, ITS USE TO PREPARE A MEDICINAL PRODUCT, PROCEDURES FOR THE PREPARATION OF SUCH COMPOUND AND INTERMEDIATE COMPOUNDS, SUCH INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND PROCEDURE TO PREPARE IT
ECSP24028270A (en) SPIROCYCLIC COMPOUNDS
AR121914A1 (en) COMPOUNDS USEFUL TO INHIBIT RET KINASE
AR129309A1 (en) DERIVATIVES OF HYDRAZINE-N-CARBOXAMIDE CYCLIC SUBSTITUTED WITH THIAZOLOARYL-METHYL
AR056165A1 (en) 1-BENZIL-4-USEFUL PIPERIDINAMINS TO TREAT PULMONARY DISEASES

Legal Events

Date Code Title Description
FB Suspension of granting procedure